Propanc Biopharma, Inc.
Research Propanc Biopharma, Inc. (PPCB) on Bullrun: market cap USD 1.13M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPPCB
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.13M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 6.36M
- Free cash flow-USD 1.14M
Valuation Snapshot
latest market cap is USD 1.13M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 58.92M | -USD 405.17K | n/a | -371.25 | USD 12.09K | USD 1.73M | USD 13.91M |
| FY2024 | USD 0 | -USD 1.82M | -USD 935.12K | n/a | -6311.87 | USD 21.09K | USD 948.27K | -USD 3.78M |
| FY2023 | USD 0 | -USD 2.66M | -USD 1.11M | n/a | -781709.75 | USD 10.05K | USD 545.92K | -USD 3.12M |
| FY2022 | USD 0 | -USD 2.66M | -USD 1.44M | n/a | -1119475.67 | USD 4.07K | USD 1.04M | -USD 3.02M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 1.13M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.22M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6 | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 120 | n/a | n/a | n/a |
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Propanc Biopharma, Inc.'s market cap?
Propanc Biopharma, Inc.'s market capitalization is USD 1.13M.
What does Propanc Biopharma, Inc. do?
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.